一、股东股份解除质押基本情况 1、本次股份解除质押基本情况 ■ 2、股东股份累计质押情况 截至公告披露日，控股股东金河控股及其一致行动人路牡丹、王志军、路漫漫、王晓英所持质押股份情 况如下： 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002688 证券简称：金河生物 公告编号：2026-014 金河生物科技股份有限公司关于控股股东部分股份解除质押的公告 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚假记载、误导性陈述或者重 大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙古金河控股有限公司（以下简 称"金河控股"）的通知，获悉金河控股所持有本公司的部分股份解除质押。具体事项如下： 特此公告。 金河生物科技股份有限公司 董 事 会 2026年2月10日 注：上表中出现合计数与各分项数值总和不符，为四舍五入所致。 截至本公告披露日，控股股东金河控股累计质押公司股份81,050,000股，占其所持股份比例36.98%；控 股股东金河控股及其一致行动人累计质押公司股份81,050,000股，占其所持股份比例31.64%，不存在平 仓风险，不存在 ...

（记者 曾健辉） 每经AI快讯，金河生物2月10日晚间发布公告称，截至本公告披露日，控股股东金河控股累计质押公司 股份8105万股，占其所持股份比例为36.98%；控股股东金河控股及其一致行动人累计质押公司股份 8105万股，占其所持股份比例为31.64%，不存在平仓风险，不存在对上市公司生产经营、公司治理、 业绩补偿义务履行等产生任何影响的情形。 每经头条（nbdtoutiao）——10倍价差刷屏！"外国人来华就医"火了，三位亲历者这样说⋯⋯ ...

金河生物科技股份有限公司 关于控股股东部分股份解除质押的公告 证券代码：002688 证券简称：金河生物 公告编号：2026-014 本公司及董事会全体人员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 金河生物科技股份有限公司（以下简称"公司"）于近日收到控股股东内蒙 古金河控股有限公司（以下简称"金河控股"）的通知，获悉金河控股所持有本 公司的部分股份解除质押。具体事项如下： 漫、王晓英所持质押股份情况如下： 一、股东股份解除质押基本情况 | | 是否为控股股东 | | 本次解除 | 占其所 | 占公司 | | 质押解 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 或第一大股东及 | | 质押股份 | 持股份 | 总股本 | 质押开始日期 | 除日期 | 质权人 | | | 其一致行动人 | | 数量（股） | 比例 | 比例 | | | | | 金河控股 | | 是 | 16,900,000 | 7.71% | 2.19% | 2024 年 6 月 17 日 | 2026 ...

证券之星消息，2月3日动物保健板块较上一交易日上涨1.15%，*ST绿康领涨。当日上证指数报收于 4067.74，上涨1.29%。深证成指报收于14127.1，上涨2.19%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 36.70 | 3.29% | 1.10万 | 3960.68万 | | 300871 | 回盛生物 | 28.30 | 2.83% | 16.64万 | 4.67亿 | | 920970 | 大禹生物 | 8.14 | 2.13% | 2.33万 | 1892.03万 | | 603566 | 普莱柯 | 14.00 | 2.04% | 6.61万 | 9186.90万 | | 920275 | 驱动力 | 9.15 | 1.78% | 1.49万 | 1360.88万 | | 920729 | 永顺生物 | 9.43 | 1.73% | 5.21万 | 4848.32万 | | 688526 | 科前生物 | ...

金河生物相关负责人对《证券日报》记者表示："我公司将以此次商誉减值后的资产优化为契机，轻装 上阵、聚焦核心、多元发力，持续夯实核心竞争力并加速培育新增长极。" 1月30日晚间，金河生物（002688）科技股份有限公司(以下简称"金河生物")发布2025年业绩预告，预 计2025年归属于上市公司股东的净利润为3000万元—4200万元。 2025年，金河生物兽用化学药品板块销售持续向好，主要产品金霉素内外销市场销量齐增，特别是海外 市场销量继续增长。该公司六期工程项目投产后，产量增加，保障了国内外市场供货需求，创造了更多 利润。环保服务板块营业收入继续增加，持续提供较多的业绩贡献。 金河生物同步披露计提商誉减值准备的公告显示，经初步减值测试，2025年度累计拟计提商誉减值准备 将影响2025年度公司合并报表归属于上市公司股东的净利润减少约1.5亿元。依此计算，若不考虑商誉 减值准备，2025年该公司预计实现归母净利润1.8亿元至1.92亿元，主营业务展现出较强的韧性与持续发 展能力。 目前，金河生物兽用疫苗板块呈现成熟产品稳增、新品加速兑现的格局。截至目前，金河生物上市销售 的疫苗产品有16个，其中蓝耳灭活疫苗 ...

Core Viewpoint - The company expects a significant decline in net profit for the year 2025, projecting a decrease of over 50% compared to the previous year, despite positive sales growth in its veterinary pharmaceutical segment and increased revenue from its environmental services division [1][2]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [1]. - The company anticipates a positive net profit but with a decline exceeding 50% [1]. Group 2: Sales and Revenue Drivers - The veterinary pharmaceutical segment continues to perform well, with increased sales in both domestic and international markets, particularly for the product "金霉素" [2]. - The completion of the company's sixth-phase project has led to increased production capacity, meeting market demand and generating additional profits [2]. - The environmental services segment has also seen a rise in revenue, contributing significantly to overall performance [2]. Group 3: Goodwill Impairment - The company plans to recognize a goodwill impairment of approximately 174.99 million yuan related to the acquisition of 金河佑本 (Jilin) Biotechnology Co., Ltd., which will reduce the net profit attributable to shareholders by about 149.81 million yuan for the year 2025 [2].

Core Viewpoint - The company has decided to suspend the research and application of the African Swine Fever freeze-dried inactivated vaccine due to significant uncertainties and challenges in the project, which will also lead to the recognition of goodwill impairment [14][19][21]. Group 1: Suspension of Vaccine Development - The board of directors unanimously approved the suspension of the African Swine Fever vaccine development project [14][20]. - The decision was made after recognizing the high technical difficulty and long regulatory approval cycles associated with the vaccine development [19][21]. - The suspension is not expected to have a significant adverse impact on the company's existing business operations [21]. Group 2: Goodwill Impairment - The company plans to recognize a goodwill impairment of approximately 17,499.47 million yuan due to the suspension of the vaccine project [30]. - This impairment is expected to reduce the net profit attributable to shareholders by about 14,981.30 million yuan for the fiscal year 2025 [30]. - The board believes that this impairment aligns with accounting standards and reflects the company's asset status more accurately [30]. Group 3: Financing Lease Business - The company approved a financing lease agreement for its subsidiary, aiming to optimize financing structure and enhance asset liquidity [33][49]. - The total financing amount is expected to be up to 14,100 million yuan, with a lease term of 30 months [33][49]. - The company will provide a guarantee for the financing lease based on its ownership percentage in the subsidiary [34][49]. Group 4: Change of Fundraising Purpose - The company has decided to change the use of unutilized fundraising from the "Animal Vaccine Production Base Construction Project" to two new projects: "Energy System and Fermentation System Optimization Project" and "3,500 tons/year Powder and Granule Automated Closed Production Line Project" [52][55]. - The total amount to be reallocated is 9,254.83 million yuan, which is approximately 11.54% of the actual net fundraising amount [53][55]. - This change is aimed at improving the efficiency of fundraising use and aligning with the company's operational needs [52][55].

证券日报网讯 1月30日，金河生物发布公告称，公司预计2025年度归属于上市公司股东的净利润为3， 000万元至4，200万元，上年同期为10，020.07万元。 （文章来源：证券日报） ...

Core Viewpoint - The animal health sector experienced a slight decline of 0.23% on January 30, with Jinhe Biological leading the drop. The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Huisheng Biological rising by 3.51% to 29.46, while Jinhe Biological fell by 2.98% to 6.51 [1][2]. - The trading volume for Huisheng Biological was 303,100 shares, with a transaction value of 901 million yuan, indicating strong market interest [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 59.82 million yuan from institutional investors, while retail investors experienced a net outflow of 81.83 million yuan, indicating a shift in investor sentiment [2][3]. - Among individual stocks, Huisheng Biological attracted a significant net inflow of 1.23 billion yuan from institutional investors, while Jinhe Biological faced a net outflow of 543.32 million yuan [3].

Core Viewpoint - The company is strategically acquiring Jilin Youben to enhance its capabilities in African swine fever vaccine research and production, aiming to increase market share and core competitiveness in the animal vaccine sector [1]. Group 1: Acquisition and Strategic Goals - The acquisition of Jilin Youben is aimed at improving the speed of research and production transformation for African swine fever vaccines [1]. - The company plans to expand its market share in the animal vaccine field through this acquisition [1]. Group 2: Compliance and Safety Upgrades - Jilin Youben and Jinhe Youben have upgraded their facilities to meet the safety requirements for vaccine production and testing, achieving biosafety level three compliance by specific dates in 2025 [1]. - By the end of Q3 2025, the company will have met all necessary qualifications for conducting clinical trials for the African swine fever vaccine [1]. Group 3: Challenges in Vaccine Development - Jilin Youben is facing challenges in finalizing a technology licensing contract with the patent transferor, which is crucial for the production and testing of the African swine fever vaccine [2]. - The company has recognized the high technical difficulty and lengthy regulatory approval process associated with African swine fever vaccine development, leading to uncertainties in project timelines and performance [2]. - As a result of these challenges, the company has decided to suspend the research and application of the freeze-dried inactivated African swine fever vaccine [2].